Parkinson’s disease recovery by GM1 oligosaccharide treatment in the B4galnt1 +/− mouse model

Elena Chiricozzi; Laura Mauri; Giulia Lunghi; Erika Di Biase; Maria Fazzari; Margherita Maggioni; Manuela Valsecchi; Simona Prioni; Nicoletta Loberto; Diego Yuri Pomè; Maria Grazia Ciampa; Pamela Fato; Gianluca Verlengia; Stefano Cattaneo; Robert Assini; Gusheng Wu; Samar Alselehdar; Robert W. Ledeen; Sandro Sonnino

doi:10.1038/s41598-019-55885-2

Parkinson’s disease recovery by GM1 oligosaccharide treatment in the B4galnt1 ^+/− mouse model

Elena Chiricozzi, Laura Mauri, Giulia Lunghi, Erika Di Biase, Maria Fazzari, Margherita Maggioni, Manuela Valsecchi, Simona Prioni, Nicoletta Loberto, Diego Yuri Pomè, Maria Grazia Ciampa, Pamela Fato, Gianluca Verlengia, Stefano Cattaneo, Robert Assini, Gusheng Wu, Samar Alselehdar, Robert W. Ledeen, Sandro Sonnino

IRCCS Ospedale San Raffaele

Research output: Contribution to journal › Article › peer-review

Abstract

Given the recent in vitro discovery that the free soluble oligosaccharide of GM1 is the bioactive portion of GM1 for neurotrophic functions, we investigated its therapeutic potential in the B4galnt1^+/− mice, a model of sporadic Parkinson’s disease. We found that the GM1 oligosaccharide, systemically administered, reaches the brain and completely rescues the physical symptoms, reduces the abnormal nigral α-synuclein content, restores nigral tyrosine hydroxylase expression and striatal neurotransmitter levels, overlapping the wild-type condition. Thus, this study supports the idea that the Parkinson’s phenotype expressed by the B4galnt1^+/− mice is due to a reduced level of neuronal ganglioside content and lack of interactions between the oligosaccharide portion of GM1 with specific membrane proteins. It also points to the therapeutic potential of the GM1 oligosaccharide for treatment of sporadic Parkinson’s disease.

Original language	English
Article number	19330
Journal	Scientific Reports
Volume	9
Issue number	1
DOIs	https://doi.org/10.1038/s41598-019-55885-2
Publication status	Published - Dec 1 2019

ASJC Scopus subject areas

General

Access to Document

10.1038/s41598-019-55885-2

Cite this

Chiricozzi, E., Mauri, L., Lunghi, G., Di Biase, E., Fazzari, M., Maggioni, M., Valsecchi, M., Prioni, S., Loberto, N., Pomè, D. Y., Ciampa, M. G., Fato, P., Verlengia, G., Cattaneo, S., Assini, R., Wu, G., Alselehdar, S., Ledeen, R. W., & Sonnino, S. (2019). Parkinson’s disease recovery by GM1 oligosaccharide treatment in the B4galnt1 ^+/− mouse model. Scientific Reports, 9(1), [19330]. https://doi.org/10.1038/s41598-019-55885-2

Chiricozzi, E, Mauri, L, Lunghi, G, Di Biase, E, Fazzari, M, Maggioni, M, Valsecchi, M, Prioni, S, Loberto, N, Pomè, DY, Ciampa, MG, Fato, P, Verlengia, G, Cattaneo, S, Assini, R, Wu, G, Alselehdar, S, Ledeen, RW & Sonnino, S 2019, 'Parkinson’s disease recovery by GM1 oligosaccharide treatment in the B4galnt1 ^+/− mouse model', Scientific Reports, vol. 9, no. 1, 19330. https://doi.org/10.1038/s41598-019-55885-2

@article{a765e38624004cd7b8e39313d9d703d7,

title = "Parkinson{\textquoteright}s disease recovery by GM1 oligosaccharide treatment in the B4galnt1 +/− mouse model",

abstract = "Given the recent in vitro discovery that the free soluble oligosaccharide of GM1 is the bioactive portion of GM1 for neurotrophic functions, we investigated its therapeutic potential in the B4galnt1+/− mice, a model of sporadic Parkinson{\textquoteright}s disease. We found that the GM1 oligosaccharide, systemically administered, reaches the brain and completely rescues the physical symptoms, reduces the abnormal nigral α-synuclein content, restores nigral tyrosine hydroxylase expression and striatal neurotransmitter levels, overlapping the wild-type condition. Thus, this study supports the idea that the Parkinson{\textquoteright}s phenotype expressed by the B4galnt1+/− mice is due to a reduced level of neuronal ganglioside content and lack of interactions between the oligosaccharide portion of GM1 with specific membrane proteins. It also points to the therapeutic potential of the GM1 oligosaccharide for treatment of sporadic Parkinson{\textquoteright}s disease.",

author = "Elena Chiricozzi and Laura Mauri and Giulia Lunghi and {Di Biase}, Erika and Maria Fazzari and Margherita Maggioni and Manuela Valsecchi and Simona Prioni and Nicoletta Loberto and Pom{\`e}, {Diego Yuri} and Ciampa, {Maria Grazia} and Pamela Fato and Gianluca Verlengia and Stefano Cattaneo and Robert Assini and Gusheng Wu and Samar Alselehdar and Ledeen, {Robert W.} and Sandro Sonnino",

year = "2019",

month = dec,

day = "1",

doi = "10.1038/s41598-019-55885-2",

language = "English",

volume = "9",

journal = "Scientific Reports",

issn = "2045-2322",

publisher = "Nature Publishing Group",

number = "1",

}

TY - JOUR

T1 - Parkinson’s disease recovery by GM1 oligosaccharide treatment in the B4galnt1 +/− mouse model

AU - Chiricozzi, Elena

AU - Mauri, Laura

AU - Lunghi, Giulia

AU - Di Biase, Erika

AU - Fazzari, Maria

AU - Maggioni, Margherita

AU - Valsecchi, Manuela

AU - Prioni, Simona

AU - Loberto, Nicoletta

AU - Pomè, Diego Yuri

AU - Ciampa, Maria Grazia

AU - Fato, Pamela

AU - Verlengia, Gianluca

AU - Cattaneo, Stefano

AU - Assini, Robert

AU - Wu, Gusheng

AU - Alselehdar, Samar

AU - Ledeen, Robert W.

AU - Sonnino, Sandro

PY - 2019/12/1

Y1 - 2019/12/1

N2 - Given the recent in vitro discovery that the free soluble oligosaccharide of GM1 is the bioactive portion of GM1 for neurotrophic functions, we investigated its therapeutic potential in the B4galnt1+/− mice, a model of sporadic Parkinson’s disease. We found that the GM1 oligosaccharide, systemically administered, reaches the brain and completely rescues the physical symptoms, reduces the abnormal nigral α-synuclein content, restores nigral tyrosine hydroxylase expression and striatal neurotransmitter levels, overlapping the wild-type condition. Thus, this study supports the idea that the Parkinson’s phenotype expressed by the B4galnt1+/− mice is due to a reduced level of neuronal ganglioside content and lack of interactions between the oligosaccharide portion of GM1 with specific membrane proteins. It also points to the therapeutic potential of the GM1 oligosaccharide for treatment of sporadic Parkinson’s disease.

AB - Given the recent in vitro discovery that the free soluble oligosaccharide of GM1 is the bioactive portion of GM1 for neurotrophic functions, we investigated its therapeutic potential in the B4galnt1+/− mice, a model of sporadic Parkinson’s disease. We found that the GM1 oligosaccharide, systemically administered, reaches the brain and completely rescues the physical symptoms, reduces the abnormal nigral α-synuclein content, restores nigral tyrosine hydroxylase expression and striatal neurotransmitter levels, overlapping the wild-type condition. Thus, this study supports the idea that the Parkinson’s phenotype expressed by the B4galnt1+/− mice is due to a reduced level of neuronal ganglioside content and lack of interactions between the oligosaccharide portion of GM1 with specific membrane proteins. It also points to the therapeutic potential of the GM1 oligosaccharide for treatment of sporadic Parkinson’s disease.

UR - http://www.scopus.com/inward/record.url?scp=85076886535&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85076886535&partnerID=8YFLogxK

U2 - 10.1038/s41598-019-55885-2

DO - 10.1038/s41598-019-55885-2

M3 - Article

C2 - 31852959

AN - SCOPUS:85076886535

SN - 2045-2322

VL - 9

JO - Scientific Reports

JF - Scientific Reports

IS - 1

M1 - 19330

ER -

Parkinson’s disease recovery by GM1 oligosaccharide treatment in the B4galnt1 ^+/− mouse model

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this